Medical Devices

With a blockbuster 2025 in the books, Boston Scientific's leadership faces intense scrutiny at upcoming investor events to prove its growth is sustainable.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

Fresh off a major drug approval, Insmed's upcoming J.P. Morgan talk is under scrutiny as investors eye pipeline updates and acquisition potential.

With strong growth and key acquisitions, Haemonetics' CEO will lay out the company's vision for 2026 at a high-stakes investor conference.

Samsung Bioepis is now directly selling its Lucentis biosimilar in Europe, a move set to increase competition and improve access to vital eye disease treatments.

South Korea's KLMBio is accelerating its global push with major investments in production and new products to capture the booming regenerative medicine market.

With a major funding round, Biobeat aims to replace bulky cuffs with a discreet patch, potentially revolutionizing hypertension care for millions.

With strong financials and new clinical data, medical device leader Penumbra is set to detail its growth strategy at healthcare's top investor event.

Treace Medical heads to the J.P. Morgan conference to showcase its surgical tech, facing tough questions on growth amid competition and market shifts.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Profound Medical raises over $42M to advance its AI-powered, incision-free therapies for cancer and other diseases, signaling strong investor confidence.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

As 'GLP-1 patch' ads flood social media for New Year's, an investigation reveals misleading marketing, a lack of science, and complex global companies.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

As CooperCompanies heads to the J.P. Morgan conference, all eyes are on CEO Al White's strategic vision for its dual vision and women's health units.

The robotics firm is outsourcing key software development in a strategic move to reduce cash burn and speed its innovative surgical system to market.

With recent FDA approval, Belgian MedTech firm Nyxoah prepares for a pivotal presentation of its unique, battery-free sleep apnea implant at JPM.